95652-74-7

Basic information

• Product Name: Methyl 4-(3,4-dichlorophenyl)-4-oxobutanoate
• Synonyms: Methyl 4-(3,4-dichlorophenyl)-4-oxobutanoate
• CAS NO: 95652-74-7
• Molecular Weight: 261.105
• Mol File: 95652-74-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Methyl 4-(3,4-dichlorophenyl)-4-oxobutanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(3,4-dichlorophenyl)-4-oxobutanoate(95652-74-7)
• EPA Substance Registry System: Methyl 4-(3,4-dichlorophenyl)-4-oxobutanoate(95652-74-7)

Safety Data

• Hazardous Substances Data: 95652-74-7(Hazardous Substances Data)

Upstream product

• 95-50-1 1,2-dichloro-benzene 
• 1490-25-1 succinic acid monomethylester chloride 
• 50597-19-8 3-(3,4-dichlorobenzoyl)-propionic acid 
• 74-88-4 methyl iodide 
• 108-30-5 succinic acid anhydride 
• 6287-38-3 3,4-dichlorobenzaldehyde 
• 77-78-1 dimethyl sulfate 
• 67-56-1 methanol 
• 23529-83-1 3,3-dimethoxycyclopropene 
• 95652-75-8 2-(3,4-Dichloro-phenyl)-5-methoxy-furan 

Downstream Products

• 92854-41-6 2-phenyl-4-(3',4'-dichlorophenyl)-4-oxo-butanoic acid 
• 191673-42-4 methyl 4-(3,4-dichlorophenyl)-4-pentenoate 
• 191018-72-1 methyl (R,S)-2-Phenyl-4-oxo-4-(3',4'-dichlorophenyl)butanoate 
• 191673-45-7 (2R)-1-azido-5-(t-butyldimethylsilyloxy)-2-(3,4-dichlorophenyl)-2-pentanol 
• 191673-44-6 (2R)-5-(t-butyldimethylsilyloxy)-2-(3,4-dichlorophenyl)pentane-1,2-diol 
• 191673-46-8 (2R)-1-amino-5-(t-butyldimethylsilyloxy)-2-(3,4-dichlorophenyl)-2-pentanol 
• 191673-43-5 tert-butyl-[4-(3,4-dichloro-phenyl)-pent-4-enyloxy]-dimethyl-silane 
• 36725-34-5 6-(3,4-dichlorophenyl)-4,5-dihydro-3(2H)-pyridazinone 

Relevant articles and documents

Sertraline derivative and preparation method and application thereof

The invention discloses a sertraline derivative or a medicinal salt thereof. The structural general formula of the sertraline derivative is shown in the specification. The sertraline derivative has a good inhibition effect on cryptococcus neoformans, particularly, the compound D16 disclosed by the invention has a relatively good inhibition effect on candida glabrata 9073, candida tropicalis 10186, cryptococcus neoformans, candida albicans 5314, candida albicans 904, candida tropicalis 10186, drug-resistant candida albicans 103 and cryptococcus gottii.

4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity

4-phenyl-4-oxo-butanoic acid derivatives for use in the treatment of the human or animal body by therepy; particularly as kynurenine-3-hydroxylase inhibitors, in the prevention and/or treatment of a neurodegenerative disease wherein the inhibition of such an enyzme is needed. The present invention further comprises a selected class of the above mentioned 4-phenyl-4-oxo-butanoic acid derivatives, their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them.

Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use

Compounds of the formula and quaternary ammonium ions thereof, wherein R1 and R2 are the same or different and are carbocyclic aryl or aromatic heterocyclic; A is methylene, carbonyl or sulfonyl; B is a single bond, C1-C4 alkylene or C2-C4, alkenylene; D is oxygen; E is C2 alkylene; G is C1-C4 alkylene or C2-C4 alkenylene; and L is -C(R4)(R5), wherein R4 and R5 together with the carbon atom to which they are attached represent a C5-C10 cycloalkyl or a C5-C10 heterocyclic. Especially preferred are compounds wherein L represents wherein J is a C1-C6 alkylene; Ar is a ring carbocyclic or aromatic heterocyclic and S*->O is a sulfoxide in which the sulfur atom is in the 5-configuration. The compounds have tachykinin receptor antagonist activity and exhibit an activity against both the NK1 and NK2 receptors.